S.Y. Chui

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Leisha A. Emens, Sylvia Adams, Carlos H. Barrios et al. · Annals of Oncology · 2021 · 468 citations · Full text

Medicine, Oncology, Pharmacology +17

Adventure-based training to promote physical activity and reduce fatigue among childhood cancer survivors: A randomized controlled trial

William Li, Ka Yan Ho, Katherine Ka Wai Lam et al. · International Journal of Nursing Studies · 2018 · 91 citations

Education, Health Promotion, Physical Education +16

Engineering a nanoscale liposome-in-liposome for in situ biochemical synthesis and multi-stage release

Colin P. Pilkington, Ignacio Gispert, S.Y. Chui et al. · Nature Chemistry · 2024 · 52 citations · Full text

Natural Sciences, Bioengineering, Biotechnology +17

LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

Nadia Harbeck, H. Zhang, Carlos H. Barrios et al. · Annals of Oncology · 2020 · 29 citations · Full text

Medicine, Oncology, Pharmacology +15

LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

C.H. Barrios, Nadia Harbeck, H.A. Zhang et al. · ESMO Open · 2023 · 25 citations · Full text

Medicine, Oncology, Pharmacotherapy +17